Compositions and methods for dissolving protein aggregates - Patents.com

Polypeptides with targeted hydrophilic and hydrophobic segments dissolve protein aggregates in neurodegenerative diseases, addressing the inadequacies of current treatments by reducing aggregate toxicity and promoting neuronal health.

JP7580171B2Active Publication Date: 2024-11-11RJK BIOPHARMA LTD
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023509613
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-08-10
Filing Date
2021-08-10
Publication Date
2024-11-11
Estimated Expiration
2041-08-10

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases, such as ALS, Alzheimer's, and Parkinson's, are inadequate as they fail to reverse progressive neuronal degeneration caused by pathogenic protein aggregates like FUS, TDP43, and alpha-synuclein, which are toxic and lead to neuronal damage.

Method used

Development of polypeptides with specific hydrophilic and hydrophobic segments that can dissolve protein aggregates by targeting them directly, using vectors like AAV to deliver these polypeptides to neurons, thereby reducing aggregate formation and promoting neuronal health.

Benefits of technology

The polypeptides effectively dissolve protein aggregates in vitro and in vivo, reducing their toxic effects and slowing or reversing neuronal degeneration, as demonstrated in cell and animal models of neurodegenerative diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580171000001
    Figure 0007580171000001
  • Figure 0007580171000002
    Figure 0007580171000002
  • Figure 0007580171000003
    Figure 0007580171000003
Patent Text Reader

Abstract

Polypeptides capable of dissolving protein aggregates are provided, as are methods of using the polypeptides to treat neurodegenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to Chinese Patent Application No. 202010796060.4, filed on August 10, 2020, the disclosure of which is incorporated herein by reference in its entirety. Technical Field

[0002] The present invention relates generally to neurobiology and neurodegenerative diseases. In particular, the present invention relates to compositions and methods for dissolving aggregates of pathogenic proteins. [Background technology]

[0002]

[0003] Protein aggregation is a common feature of many neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease. Protein aggregates in neurons, such as FUS in ALS, amyloid beta in Alzheimer's disease, alpha synuclein in Parkinson's disease, and huntingtin in Huntington's disease, are believed to be toxic and are responsible for neuronal damage or death. In general, the degree of aggregation is proportional to the severity of the neurodegenerative disease.

[0003]

[0004] Although the causes of protein aggregation in neurons are not fully understood, it is believed that aggregation-prone proteins are often supersaturated within the cell, i.e., their cellular concentration often exceeds their thermodynamic solubility, but maintain a metastable liquid-like state by buffering through heterotypic interactions. Disruption of the metastable supersaturated form leads to decreased protein solubility and, consequently, protein aggregation. Summary of the Invention [Problem to be solved by the invention]

[0004]

[0005] Some attempts have been made to develop a treatment for neurodegenerative diseases by inhibiting protein aggregation or dissolving pathogenic protein aggregates.For example, compounds that can inhibit protein aggregation are disclosed in US Patent No. 10435373, US Patent No. 9738635, US Patent No. 10889584, US Patent No. 9284309, US Patent No. 9527852 and US Patent No. 9790188. US Patent No. 9845327 discloses the inhibition of protein aggregation by promoting the activation of lysosomes.However, since there is still no known method to reverse the progressive neuronal degeneration, neurodegenerative diseases are considered to be incurable.Therefore, there is a need to develop novel compositions and methods for inhibiting protein aggregation or dissolving protein aggregates in neurons. [Means for solving the problem]

[0005]

[0006] In one aspect, the disclosure provides a polypeptide capable of dissolving protein aggregates. In some embodiments, the polypeptide comprises a hydrophilic segment and a hydrophobic segment, the hydrophilic segment has a length of 10-20 amino acid residues, at least 50% of which are Asp, Glu, Lys, or Arg, the hydrophobic segment has a length of 10-20 amino acid residues, at least 50% of which are Tyr, Phe, Trp, Leu, Ile, Val, Met, Pro, Ala, or Cys, the hydrophilic segment is at the N-terminus and the hydrophobic segment is at the C-terminus, or vice versa, and the polypeptide has a length of 20-60 amino acid residues.

[0006]

[0007] In some embodiments, the hydrophilic segment has a sequence selected from the group consisting of TX1PQX1X1SX1X1X1VX1X1PX1X1X1 (SEQ ID NO: 11), X1LX1X1SX1X1X1VX1X1X1QX1X1X1 (SEQ ID NO: 12), X1X1X1VX1X1X1X1X1VX1X1 (SEQ ID NO: 13), and X1X1SX1VQX1LX1 (SEQ ID NO: 14), wherein each X1 is Asp, Glu, Lys, or Arg, respectively.

[0007]

[0008] In some embodiments, the hydrophilic segment has a sequence selected from the group consisting of TEPQEESEEEVEEPEER (SEQ ID NO: 15), TDPQDDSDDDVDDPDDR (SEQ ID NO: 16), TKPQKKSKKKVKKPKKR (SEQ ID NO: 17), TRPQRRSRRRVRRPRRR (SEQ ID NO: 18), ELDEESEDEVEEEQEDR (SEQ ID NO: 19), KEEVDEDRDVDE (SEQ ID NO: 20), and EKSEQDLE (SEQ ID NO: 21), or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto.

[0008]

[0009] In some embodiments, the hydrophobic segment has a sequence selected from TFYDQTVSNDL (SEQ ID NO: 22), ANSAYYDAHPVTNGI (SEQ ID NO: 23), PPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 24), and EGEVAEEPNSRP (SEQ ID NO: 25), or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto.

[0009]

[0010] In some embodiments, the polypeptide is TEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQTVSNDLE (SEQ ID NO: 1), TDPQDDSDDDVDDPDDRQQTPDVVPDDSGTFYDQTVSNDLD (SEQ ID NO: 2), TKPQKKSKKKVKKPKKRQQTPKVVPDDSGTFYDQTVSNDLK (SEQ ID NO: 3), TRPQRRSRRRVRRPRRRQQTPRVVPDDSGTFYDQTVSNDLR (SEQ ID NO: 4), ELDEESED It has a sequence selected from the group consisting of EVEEEQEDRQPSPEPVQENANSAYYDAHPVTNGIE (SEQ ID NO: 8), KEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 9), and EGEVAEEPNSRPQEKSEQDLE (SEQ ID NO: 10), or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto.

[0010]

[0011] In some embodiments, the protein aggregate is a FUS aggregate, a TDP43 aggregate, a TIA1 aggregate, a C9orf72 aggregate, or a combination thereof. In some embodiments, the protein aggregate is a beta amyloid aggregate, an alpha synuclein aggregate, or a huntingtin aggregate.

[0011]

[0012] In another aspect, the present disclosure provides a polynucleotide encoding a polypeptide described herein. In some embodiments, the polynucleotide is DNA or RNA.

[0012]

[0013] In another aspect, the present disclosure provides a vector comprising the polynucleotide disclosed herein.In some embodiments, the vector is a viral vector.In some embodiments, the vector is an AAV vector.

[0013]

[0014] In another aspect, the present disclosure provides a recombinant virus comprising the polynucleotide disclosed herein. In some embodiments, the recombinant virus is AAV.

[0014]

[0015] In another aspect, the disclosure provides a host cell comprising a polynucleotide disclosed herein.

[0016] In another aspect, the present disclosure provides a pharmaceutical composition.In some embodiments, the pharmaceutical composition comprises (1) the polypeptide disclosed herein, the polynucleotide disclosed herein, the vector disclosed herein, or the recombinant virus disclosed herein.In some embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier.

[0015]

[0017] In another aspect, the present disclosure provides a method for dissolving protein aggregates in a cell.In some embodiments, the method comprises introducing a polypeptide disclosed herein into a cell.In some embodiments, the cell is a neuronal cell.In some embodiments, the protein aggregate is a FUS protein aggregate, and the cell is a motor neuron.In some embodiments, the cell is in vitro or in vivo.

[0016]

[0018] In another aspect, the disclosure provides a method for treating a neurodegenerative disease in a subject in need of such treatment. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. In some embodiments, the neurodegenerative disease is selected from frontotemporal dementia, amyotrophic lateral sclerosis, corticobasal degeneration, Lewy body dementia, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic grain disease, Alzheimer's disease, Kii Peninsula Parkinson's / dementia complex, progressive supranuclear palsy, and Pick's disease. In some embodiments, the pharmaceutical composition is administered to the central nervous system. In some embodiments, the pharmaceutical composition is administered via spinal injection, intrathecal injection, intraventricular injection, intracerebral injection, or intrahippocampal injection.

[0017]

[0019] In yet another aspect, the disclosure provides a method for identifying a polypeptide capable of dissolving protein aggregates. In some embodiments, the method includes identifying a protein having a denatured region, the denatured region comprising (a) at least two amino acid residues of Gln, (b) at least six hydrophilic amino acid residues selected from Arg, Lys, Asp, Glu, and Asn, and (c) at least six hydrophobic amino acid residues selected from Phe, Cys, Leu, Val, and Ile; generating a polypeptide consisting essentially of the denatured region; contacting the polypeptide with protein aggregates; and determining that the polypeptide dissolves protein aggregates. In some embodiments, the polypeptide has a length of 20-60 amino acid residues. In some embodiments, the polypeptide comprises a hydrophilic segment at the N-terminus and a hydrophobic segment at the C-terminus, or vice versa.

[0018]

[0020] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure. The disclosure may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. [Brief description of the drawings]

[0019] [Figure 1]

[0021] FIG. 1 shows the sequences of exemplary polypeptides of the present disclosure. [Diagram 2]

[0022] Polypeptides RJK001-RJK004 dissolved FUS protein aggregates in vitro. Prokaryotically expressed and purified FUS protein (10 uM FUS at pH 7.5) was induced to form phase-separated droplets in vitro. Polypeptides RJK001-RJK007 (30 uM) were added drop by drop to the FUS droplets. Observations were performed continuously via confocal laser microscope. The image on the left is a microscopic image immediately after adding the polypeptides. The image in the middle is a microscopic image after adding the polypeptides for 40 seconds. The image on the right is a microscopic image after adding the polypeptides for 80 seconds. [Diagram 3]

[0023] Polypeptides RJK001-RJK004 dissolved TDP-43 protein aggregates in vitro. Prokaryotically expressed and purified TDP43 protein (10 uM TDP-43 at pH 7.5) was induced to form phase-separated droplets in vitro. Polypeptides RJK001-RJK007 (30 uM) were added drop by drop to the TDP43 droplets. Observations were performed continuously via confocal laser microscope. The image on the left is a microscopic image immediately after the addition of the polypeptide. The image in the middle is a microscopic image when the polypeptide was added for 40 seconds. The image on the right is a microscopic image when the polypeptide was added for 80 seconds. [Figure 4]

[0024] Figure 1 shows that polypeptides RJK001-RJK004 dissolved TIA1 protein aggregates in vitro. Polypeptides RJK001-RJK007 (90 uM) were added dropwise to a TIA1 protein solution (pH 7.5, 30 uM TIA1) with protein aggregates. Observations were performed continuously via a confocal laser microscope. The image on the left is a microscopic image immediately after the polypeptides were added. The image in the middle is a microscopic image when the polypeptides were added for 40 seconds. The image on the right is a microscopic image when the polypeptides were added for 80 seconds. [Diagram 5]

[0025] Figure 1 shows that polypeptides RJK001-RJK004 dissolved GR50-GFP protein aggregates in vitro. Polypeptides RJK001-RJK007 (10 uM) were added dropwise to a GR50-GFP protein solution (translated from RNA not encoding C9orf72, 10 uM, in 10% PEG) with protein aggregates. Observations were performed continuously via a confocal laser microscope. The image on the left is a microscopic image immediately after the addition of the polypeptide. The image in the middle is a microscopic image when the polypeptide was added for 40 seconds. The image on the right is a microscopic image when the polypeptide was added for 80 seconds. [Figure 6]

[0026] Figure 1 shows the effect of RJK001-RJK007 polypeptides on FUS protein aggregates in SH-SY5Y cell model. Polypeptides RJK001-RJK004 and control polypeptides RJK005-RJK007 were transfected into SH-SY5Y cell model overexpressing FUS-mCherry after heat stimulation. G3BP1 staining represents stress granules. RJK001-RJK004 polypeptides had a significant dissolving effect on ALS pathogenic FUS aggregates, while control polypeptides RJK005-RJK007 had no effect on dissolving pathogenic FUS protein aggregates. [Figure 7]

[0027] Figure 1 shows the effect of RJK001-RJK007 polypeptides on TDP-43 protein aggregates in SH-SY5Y cell model. Polypeptides RJK001-RJK004 and control polypeptides RJK005-RJK007 were transfected into SH-SY5Y cell model overexpressing TDP-43-mCherry after heat stimulation. G3BP1 staining represents stress granules. RJK001-RJK004 polypeptides had a significant dissolving effect on ALS pathogenic TDP-43 aggregates, while control polypeptides RJK005-RJK007 had no effect on dissolving pathogenic TDP-43 protein aggregates. [Figure 8]

[0028] Figure 1 shows the effect of polypeptide RJK001 and control polypeptide RJK005 on the pathogenic FUS protein of ALS on primary cultured mouse motor neurons. The RJK001 polypeptide enhanced the dissolution of FUS-GFP protein aggregates in mouse motor neurons, whereas the control polypeptide had no effect on the dissolution of pathogenic FUS protein aggregates. Real-time imaging techniques using a fluorescent microscope were used to observe the cell cultures. The leftmost image shows motor neurons and protein aggregates on day 10 of in vitro culture. The second and third images from the left are microscopic images immediately after the addition of the polypeptide (0 min), the middle images are microscopic images at different time points (30 min, 60 min, 90 min) after the addition of the polypeptide, and the rightmost image is a microscopic image 120 min after the addition of the polypeptide. [Figure 9]

[0029] Figure 1 shows the effect of polypeptide RJK001 and control polypeptide RJK005 on ALS pathogenic SOD1(G93A) protein in primary cultured mouse motor neurons. RJK001 polypeptide enhanced dissolution of SOD1(G93A)-GFP protein aggregates in mouse motor neurons, while the control polypeptide had no effect on dissolution of protein aggregates. Real-time imaging technique using a fluorescent microscope was used to observe the cell culture. The left panel is polypeptide RJK001, and the right panel is control polypeptide RJK005. The left image in each panel shows the image of motor neurons and protein aggregates on the 10th day of in vitro culture. The right image in each panel is a microscope image 24 hours after adding the polypeptide. [Figure 10]

[0030] Figure 1 shows that the introduction of RJK001 polypeptide into SOD1(G93A) transgenic mice can effectively alleviate motor dysfunction in the animals. Two-month-old SOD1(G93A) transgenic mice were intrathecally injected with normal saline, AAV-RJK001, or AAV-RJK005. The results of the open field experiment on the motor function of mice are shown as open bars: saline (control group), RJK001 (AAV-RJK001 virus injection), and RJK005 (AAV-RJK005 virus injection). The gait score of the open field experiment after 6 weeks of treatment is expressed by the time required per unit distance. The longer the time, the worse the motor performance. Compared with the RJK005 and control groups, the motor performance of the mice in the RJK001 experimental group was significantly improved. [Figure 11]

[0031] Polypeptides RJG001-RJG003 dissolved FUS protein aggregates in vitro. Prokaryotically expressed and purified FUS protein (pH 7.5, 10 uM FUS) was induced to form phase-separated droplets in vitro. Polypeptides RJG001-RJG003 and RJK005 (30 uM) were added drop by drop to the FUS droplets. Observations were performed continuously via confocal laser microscope. The image on the left is a microscope image immediately after the addition of the polypeptides. The image in the middle is a microscope image when the polypeptides were added for 40 seconds. The image on the right is a microscope image when the polypeptides were added for 80 seconds. [Figure 12]

[0032] Figure 1 shows the effect of RJG001-RJG003 polypeptides on FUS protein aggregates in SH-SY5Y cell model. Polypeptides RJG001-RJG003 and control polypeptide RJK005 were transfected into SH-SY5Y cell model overexpressing FUS-mCherry after heat stimulation. G3BP1 staining represents stress granules. RJG001-RJG003 polypeptides had a significant dissolving effect on ALS pathogenic FUS aggregates, whereas control polypeptide RJK005 had no effect on pathogenic FUS protein aggregates. [Figure 13]

[0033] FIG. 1 shows the amino acid code. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020]

[0034] Before describing the present disclosure in further detail, it is to be understood that the present disclosure is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure will be limited only by the appended claims.

[0021]

[0035] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of this disclosure, the preferred methods and materials are described below.

[0022]

[0036] All publications and patents cited herein are incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference, and are incorporated by reference to disclose and describe the methods and / or materials in connection with which the publications are cited. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the disclosure is not entitled to antedate such publication by virtue of prior disclosure. Further, the dates of publication provided may be different from the actual publication dates, which may need to be independently confirmed.

[0023]

[0037] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has separate components and features that may be readily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the disclosure. Any shown method may be carried out in the order of events shown or in any other order that is logically possible.

[0024]

[0038] definition

[0039] It should be understood that both the general description above and the detailed description below are exemplary and explanatory only and are not intended to limit the invention as set forth in the claims. In this application, the use of the singular includes the plural unless specifically stated otherwise. In this disclosure, the term "or" is used to mean "and / or" unless clearly indicated to refer to alternatives only or unless the alternatives are mutually exclusive. As used herein, "another" can mean at least a second, or a third or more. Furthermore, the use of the term "including" and other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components that include one unit and elements and components that include two or more subunits, unless specifically stated otherwise. Also, the use of the term "portion" can include a portion of a moiety, or the entire moiety.

[0025]

[0040] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise.

[0041] As used herein, the term "administration" means providing a pharmaceutical agent or composition to a subject, and includes, but is not limited to, administration by a medical professional and self-administration.

[0026]

[0042] The term "amino acid" as used herein refers to an organic compound having an amine (-NH2) functional group and a carboxyl (-COOH) functional group and a side chain specific to each amino acid. The names of amino acids are also represented in this disclosure by standard single-letter symbols or three-letter codes.

[0027]

[0043] A "cell" as used herein may be a prokaryotic or eukaryotic cell. Prokaryotic cells include, for example, bacteria. Eukaryotic cells include, for example, fungi, plant cells, and animal cells. Preferably, the cells described herein are animal cells.Types of animal cells (e.g., mammalian or human cells) include, for example, cells of the nervous system or nervous organs, such as neurons, glioblasts (e.g., astrocytes and oligodendrocytes), microglia, giant cell neurosecretory cells, stellate cells, Bechtel cells, and pituitary cells (e.g., gonadotropes, adrenocorticotropes, thyrotropes, somatotropes, and prolactinocytes); cells of the circulatory / immune system or circulatory / immune organs, such as B cells, T cells (cytotoxic T cells, natural killer T cells, regulatory T cells, helper T cells), natural killer cells, granulocytes (e.g., basophils, eosinophils, neutrophils, and hypersegmented neutrophils), monocytes or macrophages, erythrocytes (e.g., reticulocytes), mast cells, platelets or megakaryocytes, and dendritic cells; cells of the endocrine system or endocrine organs, such as thyroid cells (e.g., thyroid epithelial cells, parafollicular cells), parathyroid cells (e.g., parathyroid chief cells, eosinophilic cells), adrenal cells (e.g., chromaffin cells), and cells of the pineal gland (e.g., pineal cells); cells of the respiratory system or organs, such as alveoli, e.g., pneumocytes (type I pneumocytes and type II pneumocytes), Clara cells, goblet cells, alveolar macrophages; cells of the circulatory system or circulatory organs, e.g., cardiac myocytes and pericytes; cells of the digestive system or digestive organs, e.g., gastric chief cells, parietal cells, goblet cells, Paneth cells, G cells, D cells, ECL cells, I cells, K cells, S cells, enteroendocrine cells, enterochromaffin cells, APUD cells, liver cells (e.g., hepatocytes and Kupffer cells); cells of the integumentary system or integumentary organs, e.g., bone cells (e.g., osteoblasts, osteocytes, and osteoclasts), dental cells (e.g., cementum blasts, osteoblasts, osteoblasts, osteoclasts, osteoblast ... cells and ameloblasts), cells of cartilage (e.g., chondroblasts and chondrocytes), cells of skin / hair (e.g., hair follicles, keratinocytes, and melanocytes (nevus cells), muscle cells (e.g., myocytes), adipocytes, fibroblasts, and tendon cells); cells of the urinary system or urinary organs (e.g., podocytes, juxtaglomerular cells, intraglomerular mesangial cells, extraglomerular mesangial cells, brush border cells of the renal proximal tubule, and macula densa cells); and cells of the reproductive system or reproductive organs (e.g., sperm, Sertoli cells, Leydig cells, eggs, oocytes).The cell can be a normal, healthy cell, or a diseased or unhealthy cell (e.g., a cancer cell). The mammalian cell can be a rodent cell, such as a mouse, rat, or hamster cell. The mammalian cell can be a lagomorph cell, such as a rabbit cell. The mammalian cell can also be a primate cell, such as a human cell.

[0028]

[0044] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of drug sufficient to prevent, treat, reduce, and / or ameliorate the symptoms and / or underlying causes of any disorder or disease, or an amount of drug sufficient to produce a desired effect on cells. In one embodiment, a "therapeutically effective amount" is an amount sufficient to reduce or eliminate the symptoms of a disease. In another embodiment, a therapeutically effective amount is an amount sufficient to overcome the disease itself.

[0029]

[0045] The term "host cell" refers to a cell that has been transformed or can be transformed with a nucleic acid sequence and thereby expresses a protein of interest. The term includes the progeny of a parent cell, which may or may not be identical in morphology or genetic make-up to the original parent cell, provided that the gene of interest is present.

[0030]

[0046] The term "nucleic acid" or "polynucleotide" as used herein refers to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) and polymers thereof in single-stranded or double-stranded form. Unless otherwise indicated, a particular polynucleotide sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is replaced with mixed bases and / or deoxyinosine residues (see Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0031]

[0047] "Percent (%) sequence identity" for an amino acid sequence (or nucleic acid sequence) is defined as the percentage of amino acid (or nucleic acid) residues in a candidate sequence that are identical to the amino acid (or nucleic acid) residues in a reference sequence after aligning the sequences and introducing gaps, if necessary, to maximize the number of identical amino acids (or nucleic acids). Conservative substitutions of amino acid residues may or may not be considered identical residues. Alignments for the purpose of determining percent amino acid (or nucleic acid) sequence identity can be performed using publicly available tools such as, for example, BLASTN, BLASTp (available at the National Center for Biotechnology Information (NCBI) website, see also Altschul SF et al., J. Mol. Biol., 215:403-410 (1990); Stephen F. et al., Nucleic Acids Res., 25:3389-3402 (1997)), ClustalW2 (available at the European Bioinformatics Institute website, see also Higgins DG et al., Methods in Enzymology, 266:383-402 (1996); Larkin MA et al., Bioinformatics (Oxford, England), 23(21):2947-8 (2007)), and ALIGN or Megalign (DNASTAR) software. One skilled in the art can use the default parameters provided by the tool or can customize the parameters as needed for the alignment, such as by selecting an appropriate algorithm.

[0032]

[0048] The term "polypeptide" or "protein" refers to a sequence of at least two amino acids linked together by a peptide bond. Polypeptides and proteins may contain moieties in addition to amino acids (e.g., may be glycosylated) and / or may be otherwise processed or modified. Those skilled in the art will understand that a "polypeptide" or "protein" may be a complete polypeptide chain (with or without a signal sequence) as produced by a cell, or a functional portion thereof. Those skilled in the art will further understand that a polypeptide or protein may sometimes include two or more polypeptide chains, for example, linked by one or more disulfide bonds or linked by other means. The term also includes amino acid polymers in which one or more amino acids are chemical analogs of the corresponding naturally occurring amino acids and polymers.

[0033]

[0049] The expression "pharmaceutical acceptable carrier" as used herein means a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in the transport or transfer of a compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and non-toxic to the patient. Some examples of materials which may serve as pharma- ceutically acceptable carriers include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives, e.g., sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates, and / or polyanhydrides; and other non-toxic compatible substances utilized in pharmaceutical formulations.

[0034]

[0050] The term "protein aggregates" as used herein refers to protein aggregation found inside or outside a cell. In some embodiments, the protein is an intrinsically disordered protein or a misfolded protein. In some embodiments, aggregation occurs when the concentration of the protein exceeds the solubility of the protein. In some embodiments, the concentration of the protein exceeds the thermodynamic solubility, but the protein maintains a metastable liquid-like state by buffering through heterotypic interactions. Disorder of the metastable form of the protein causes a decrease in protein solubility, resulting in protein aggregation.

[0035]

[0051] The term "recombinant" when used with respect to a polypeptide (e.g., antibody, antigen) or polynucleotide refers to a polypeptide or polynucleotide produced by recombinant methods. A "recombinant polypeptide" includes any polypeptide expressed from a recombinant polynucleotide. A "recombinant polynucleotide" includes any polynucleotide that has been modified by the introduction of at least one exogenous (i.e., foreign, typically heterologous) nucleotide or the alteration of at least one naturally occurring nucleotide component of the polynucleotide, although the polynucleotide may not necessarily contain all of the coding sequence or regulatory elements naturally associated with the coding sequence. A "recombinant vector" refers to a non-naturally occurring vector, including, for example, a vector that includes a recombinant polynucleotide sequence.

[0036]

[0052] As used herein, the term "subject" refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Human includes prenatal and postnatal forms. In many embodiments, the subject is a human being. The subject may be a patient, which refers to a human who visits a health care provider for diagnosis or treatment of a disease. The term "subject" is used herein interchangeably with "individual" or "patient". A subject may be afflicted with or susceptible to a disease or disorder, but may or may not show symptoms of the disease or disorder.

[0037]

[0053] "Treating" a condition or "treatment" of a condition, as used herein, includes preventing or alleviating the condition, slowing the onset or rate of development of the condition, reducing the risk of developing the condition, preventing or delaying the onset of symptoms associated with the condition, reducing or terminating symptoms associated with the condition, causing complete or partial regression of the condition, curing the condition, or some combination thereof.

[0038]

[0054] As used herein, "vector" refers to a nucleic acid molecule that, when introduced into a host cell, produces a transformed host cell. A vector may contain a nucleic acid sequence that allows the vector to replicate in a host cell, such as an origin of replication. A vector may also contain one or more therapeutic genes and / or selectable marker genes, as well as other genetic elements known in the art. A vector can transduce, transform, or infect a cell, thereby causing the cell to express a nucleic acid and / or protein that is not native to the cell. A vector may optionally contain materials that aid in the achievement of the entry of the nucleic acid into the cell, such as a viral particle, a liposome, a protein coating, or the like.

[0039]

[0055] Composition for dissolving protein aggregates - Patents.com

[0056] Protein aggregation is a biological phenomenon in which intrinsically disordered or misfolded proteins aggregate (i.e., accumulate and clump together) either inside or outside a cell. Protein structure is stabilized by non-covalent interactions and disulfide bonds between two cysteine ​​residues. Non-covalent interactions include ionic interactions and weak van der Waals interactions. Ionic interactions form between anions and cations, forming salt bridges that help stabilize proteins. Van der Waals interactions include non-polar and polar interactions (i.e., hydrogen bonds, dipole-dipole bonds). These play an important role in the formation of secondary structures, e.g., alpha helices or beta sheets, and in the tertiary structure of proteins. The interactions between amino acid residues in a particular protein are very important in the final structure of that protein.

[0040]

[0057] If there is a change in the non-covalent interactions, which can occur with changes in amino acid sequence, the protein is prone to misfolding or unfolding. In these cases, if the cell does not help the protein refold or degrade the unfolded protein, the unfolded / misfolded protein may aggregate, in which exposed hydrophobic parts of the protein may interact with exposed hydrophobic patches of other proteins. Three main types of protein aggregates can be formed: amorphous aggregates, oligomers, and amyloid fibrils. Misfolded protein aggregates are often correlated with disease. For example, protein aggregates have been implicated in a wide range of neurodegenerative diseases, including ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease, and prion diseases.

[0041]

[0058] The present disclosure is based on the surprising discovery that fragments of certain natural proteins, such as G3BP1, can dissolve protein aggregates. In particular, such fragments are generally amphiphilic, i.e., they contain a hydrophilic segment at one end and a hydrophobic segment at the other. The inventors have also found that certain variants of the fragments, in which hydrophilic amino acid residues are replaced by other hydrophilic amino acid residues, retain the protein aggregate dissolving properties.

[0042]

[0059] Thus, in one aspect, the present disclosure provides a polypeptide capable of dissolving protein aggregates. In some embodiments, the polypeptide comprises a hydrophilic segment and a hydrophobic segment, the hydrophilic segment having a length of 10-20 amino acid residues, at least 50% of which are Asp, Glu, Lys, or Arg, the hydrophobic segment having a length of 10-20 amino acid residues, at least 50% of which are Tyr, Phe, Trp, Leu, Ile, Val, Met, Pro, Ala, or Cys, the hydrophilic segment being at the N-terminus and the hydrophobic segment being at the C-terminus, or vice versa, and the polypeptide having a length of 20-60 amino acid residues.

[0043]

[0060] In some embodiments, the hydrophilic segment has a sequence selected from the group consisting of TX1PQX1X1SX1X1X1VX1X1PX1X1X1 (SEQ ID NO: 11), X1LX1X1SX1X1X1VX1X1X1QX1X1X1 (SEQ ID NO: 12), X1X1X1VX1X1X1X1X1VX1X1 (SEQ ID NO: 13), and X1X1SX1VQX1LX1 (SEQ ID NO: 14), wherein each X1 is Asp, Glu, Lys, or Arg, respectively.

[0044]

[0061] In some embodiments, the hydrophilic segment has a sequence selected from the group consisting of TEPQEESEEEVEEPEER (SEQ ID NO: 15), TDPQDDSDDDVDDPDDR (SEQ ID NO: 16), TKPQKKSKKKVKKPKKR (SEQ ID NO: 17), TRPQRRSRRRVRRPRRR (SEQ ID NO: 18), ELDEESEDEVEEEQEDR (SEQ ID NO: 19), KEEVDEDRDVDE (SEQ ID NO: 20), and EKSEQDLE (SEQ ID NO: 21), or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto.

[0045]

[0062] In some embodiments, the hydrophobic segment has a sequence selected from TFYDQTVSNDL (SEQ ID NO: 22), ANSAYYDAHPVTNGI (SEQ ID NO: 23), PPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 24), and EGEVAEEPNSRP (SEQ ID NO: 25), or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto.

[0046]

[0063] 2. The polypeptide of claim 1, having a sequence selected from the group consisting of TEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQTVSNDLE (SEQ ID NO: 1), TDPQDDSDDDVDDPDDRQQTPDVVPDDSGTFYDQTVSNDLD (SEQ ID NO: 2), TKPQKKSKKKVKKPKKRQQTPKVVPDDSGTFYDQTVSNDLK (SEQ ID NO: 3), TRPQRRSRRRVRRPRRRQQTPRVVPDDSGTFYDQTVSNDLR (SEQ ID NO: 4), ELDEESEDEVEEEQEDRQPSPEPVQENANSAYYDAHPVTNGIE (SEQ ID NO: 8), KEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 9), and EGEVAEEPNSRPQEKSEQDLE (SEQ ID NO: 10), or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto.

[0047]

[0064] In some embodiments, protein aggregates are the cause of neurodegenerative disease.In some embodiments, protein aggregates are FUS aggregates, TDP43 aggregates, TIA1 aggregates, C9orf72 aggregates, or combinations thereof.In some embodiments, protein aggregates are beta amyloid aggregates, alpha synuclein aggregates, or huntingtin aggregates.

[0048]

[0065] In another aspect, the present disclosure provides a polynucleotide that encodes the polypeptide described herein.In some embodiments, the polynucleotide is DNA or RNA.In some embodiments, the polynucleotide is single-stranded DNA or double-stranded DNA.

[0049]

[0066] In another aspect, the present disclosure provides a vector comprising the polynucleotide disclosed herein.Typically, the vector further comprises additional elements that facilitate the expression of polypeptide, such as promoter, enhancer, polyA region, etc.In some embodiments, the vector is a virus vector.In some embodiments, the vector is an adeno-associated virus (AAV) vector.In some embodiments, the AAV vector further comprises ITR sequence.

[0050]

[0067] In another aspect, the present disclosure provides recombinant virus comprising the polynucleotide disclosed herein.In some embodiments, the recombinant virus is AAV.In some embodiments, the AAV has serotype selected from AAV1, AAV2, AAV3, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrh10, AAV11 and AAV12.

[0051]

[0068] In another aspect, the disclosure provides a host cell comprising a polynucleotide disclosed herein. The host cell can be used to express a polypeptide disclosed herein or to produce a virus disclosed herein.

[0052]

[0069] In another aspect, the disclosure provides a pharmaceutical composition comprising the polypeptide, polynucleotide, vector, recombinant virus, or host cell disclosed herein. Such compositions comprise a prophylactically or therapeutically effective amount of the polypeptide, polynucleotide, vector, recombinant virus, or host cell, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the federal or state government, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeias for use in animals, particularly humans. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is a particular carrier when the pharmaceutical composition is administered intravenously. Saline and aqueous dextrose and glycerol solutions can also be utilized as liquid carriers, particularly for injectable solutions. Other suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, wheat, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.

[0053]

[0070] The compositions may also contain minor amounts of wetting or emulsifying agents or pH buffering agents, if necessary. These compositions may take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained release formulations, and the like. Examples of suitable pharmaceutical agents are described in "Remington's Pharmaceutical Sciences". Such compositions contain a prophylactically or therapeutically effective amount of the polypeptide, polynucleotide, vector, recombinant virus, or host cell, together with a suitable amount of carrier to provide the form for proper administration to the patient. The formulation should be compatible with the mode of administration, which may be intrathecal, intravenous, intraarterial, buccal, intranasal, aerosol, bronchial inhalation, or delivery by mechanical ventilation. If the composition is administered by injection, an ampoule of sterile water for injection or saline may be prepared so that the ingredients can be mixed prior to administration.

[0054]

[0071] The compositions of the present disclosure can be formulated as neutral or salt form.Pharmaceutically acceptable salts include salts formed with anions, such as salts derived from hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid, etc., and salts formed with cations, such as salts derived from sodium, potassium, ammonium, calcium, ferric hydroxide, isopropylamine, triethylamine, 2-ethylaminoethanol, histidine, procaine, etc.

[0055]

[0072] Identification method

[0073] In another aspect, the present disclosure provides a method for identifying a polypeptide capable of dissolving protein aggregates. In some embodiments, the method includes identifying an intrinsically unfolded protein having a denatured region, the denatured region comprising (a) at least two amino acid residues consisting of Gln, and / or (b) at least six hydrophilic amino acid residues selected from Arg, Lys, Asp, Glu, and Asn, and / or (c) at least six hydrophobic amino acid residues selected from Phe, Cys, Leu, Val, and Ile; generating a polypeptide consisting essentially of the denatured region; contacting the polypeptide with protein aggregates; and determining that the polypeptide dissolves protein aggregates. In some embodiments, the polypeptide has a length of 20-60 amino acid residues. In some embodiments, the polypeptide comprises a hydrophilic segment at the N-terminus and a hydrophobic segment at the C-terminus, or vice versa. In some embodiments, the protein is a natural intrinsically unfolded protein.

[0056]

[0074] In some embodiments, the modified region comprises at least 3, 4, or 5 Gln amino acid residues. In some embodiments, the modified region comprises at least 7, 8, 9, or 10 hydrophilic amino acid residues selected from Arg, Lys, Asp, Glu, and Asn. In some embodiments, the modified region comprises at least 7, 8, 9, or 10 hydrophobic amino acid residues selected from Phe, Cys, Leu, Val, and Ile.

[0057]

[0075] An intrinsically disordered protein is a protein that has no fixed or disordered three-dimensional structure, typically in the absence of its interaction partners, such as other proteins or RNA. An intrinsically disordered protein may be completely unstructured or only partially structured. Natural intrinsically disordered proteins are known in the art through literature or databases. For example, the DisProt database collects intrinsically disordered proteins selected from the literature (Hatos, A. et al., DisProt: Intrinsic protein disorder annotation in 2020, Nucleic Acids Research (2020) 48 (D1), 269-276). In some embodiments, a database (e.g., the DisProt database) is searched to identify intrinsically disordered proteins that have disordered regions with the characteristics as described.

[0058]

[0076] After identifying the denatured region that meets the criteria as described, a polypeptide that essentially consists of the denatured region can be recombinantly produced using approaches known in the art.This polypeptide is then tested for its ability to dissolve protein aggregates, such as FUS aggregates, TDP43 aggregates, TIA1 aggregates, and C9orf72 aggregates.In some embodiments, the polypeptide can dissolve at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% of protein aggregates.

[0059]

[0077] A variant of a polypeptide can be created by replacing amino acid residues in the polypeptide so that the variant has a sequence that is at least 90% identical to the polypeptide or has a sequence that differs from the polypeptide by 1, 2, 3, 4, or 5 amino acid residues. The created variant can then be tested for its ability to dissolve protein aggregates. In some embodiments, the variant has an improved ability to dissolve protein aggregates compared to the polypeptide from which the variant is derived.

[0060]

[0078] How to use

[0079] In another aspect, the disclosure provides a method for dissolving protein aggregates in a cell. In some embodiments, the method comprises introducing a polypeptide disclosed herein into a cell. In some embodiments, the cell is a neuron. In some embodiments, the protein aggregate is a FUS protein aggregate, a TDP-43 protein aggregate, a TIA1 protein aggregate, a beta amyloid protein aggregate, an alpha synuclein protein aggregate, or a huntingtin protein aggregate. In some embodiments, the polypeptide is introduced into a cell by contacting the cell with the polypeptide. In some embodiments, the polypeptide is introduced into a cell by introducing a polynucleotide encoding a polypeptide disclosed herein into the cell, thereby allowing the cell to express the polypeptide. In some embodiments, the polynucleotide is introduced into a cell by transforming the cell with a vector or virus comprising the polynucleotide or by transfecting the cell with the vector or virus.

[0061]

[0080] In yet another aspect, the present disclosure provides a method for treating a disease or condition associated with protein aggregation. In some embodiments, the disease or condition associated with protein aggregation is a neurodegenerative disease. Neurodegenerative diseases lead to progressive loss of neuronal structure or function, and ultimately cell death. Examples of neurodegenerative diseases include, but are not limited to, frontotemporal dementia, amyotrophic lateral sclerosis (ALS), corticobasal degeneration, dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic grain disease, Alzheimer's disease, Kii Peninsula Parkinson's / dementia complex, progressive supranuclear palsy, and Pick's disease.

[0062]

[0081] Amyotrophic lateral sclerosis (ALS) involves degeneration of upper motor neurons (UMN) and lower motor neurons (LMN), with symptoms of gradual progression of skeletal muscle weakness. Missense mutations in the gene encoding the antioxidant enzyme Cu / Zn superoxide dismutase 1 (SOD1) have been found in a subset of patients with familial ALS. However, the pathogenic mechanisms underlying the toxicity of SOD1 mutants remain to be elucidated. TDP-43 and FUS protein aggregates have also been associated with the disease in some cases, and mutations in chromosome 9 (C9orf72) are thought to be the most commonly known cause of sporadic ALS.

[0063]

[0082] Alzheimer's disease (AD) is a chronic neurodegenerative disorder that results in loss of neurons and synapses in the cerebral cortex and certain subcortical structures, producing gross atrophy in the temporal lobe, in the parietal lobe, and in multiple parts of the frontal cortex and cingulate gyrus. AD pathology is primarily characterized by the presence of senile plaques and neurofibrillary tangles. Plaques are made of small peptides, typically 39-43 amino acids long, called beta amyloid (also written as Abeta or Aβ). Beta amyloid is a fragment of a larger protein called amyloid precursor protein (APP), a transmembrane protein that enters through the membrane of neurons. APP is thought to have a role in normal neuronal growth, survival, and repair after injury. APP is cleaved into smaller fragments by enzymes such as gamma secretase and beta secretase. One of these fragments gives rise to fibrils of beta amyloid that can self-assemble into dense extracellular deposits known as senile plaques or amyloid plaques.

[0064]

[0083] Parkinson's disease (PD) is the second most common neurodegenerative disorder. It typically manifests as bradykinesia, rigidity, resting tremor, and impaired postural reflexes. PD is primarily characterized by the death of dopaminergic neurons in the substantia nigra, a region of the midbrain. The cause of this selective cell death is unknown. In particular, alpha-synuclein-ubiquitin complexes and aggregates have been observed to accumulate in Lewy bodies within affected neurons. It is believed that defects in the mechanisms and regulation of protein transport, such as RAB1, may be responsible for this disease mechanism. Impaired axonal transport of alpha-synuclein may also result in the accumulation of alpha-synuclein in Lewy bodies. Experiments have revealed reduced transport rates of both wild-type and two mutant alpha-synucleins associated with familial Parkinson's disease through the axons of cultured neurons.

[0065]

[0084] Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by mutations in the huntingtin gene (HTT). HD is characterized by loss of medium spiny neurons and astrogliosis. The first brain region to be significantly affected is the striatum, followed by degeneration of the frontal and temporal cortices. The subthalamic nucleus of the striatum sends control signals to the globus pallidus, which initiates and regulates movement. Thus, weakened signals from the subthalamic nucleus reduce the initiation and regulation of movement, resulting in the characteristic movements of this disorder, especially chorea. HD is caused by the expansion of a polyglutamine tract in the huntingtin gene, which gives rise to mutant huntingtin. Mutant huntingtin aggregates form as inclusions in neurons and can be directly toxic. In addition, they can damage molecular motors and microtubules, interfering with normal axonal transport and impairing the transport of important cargoes such as BDNF.

[0066]

[0085] In some embodiments, the method of treating a disease or condition associated with protein aggregation comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition disclosed herein.

[0067]

[0086] The therapeutically effective amount of the pharmaceutical compositions provided herein will depend on a variety of factors known in the art, such as the type of disease being treated, the subject's weight, age, past medical history, current medications, health status, immune status and potential cross-reactions, allergies, sensitivities and side effects, as well as the route and type of administration, the severity and onset of the disease, and the discretion of the attending physician or veterinarian. In certain embodiments, the pharmaceutical compositions provided herein may be administered at a therapeutically effective dosage of about 0.001 mg / kg to about 100 mg / kg, one or more times per day (e.g., about 0.001 mg / kg, about 0.3 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, about 60 mg / kg, about 65 mg / kg, about 70 mg / kg, about 75 mg / kg, about 80 mg / kg, about 85 mg / kg, about 90 mg / kg, about 95 mg / kg, or about 100 mg / kg, one or more times per day). In certain embodiments, the pharmaceutical composition is administered at a dosage of about 50 mg / kg or less, and in certain embodiments, the dosage is 20 mg / kg or less, 10 mg / kg or less, 3 mg / kg or less, 1 mg / kg or less, 0.3 mg / kg or less, 0.1 mg / kg or less, or 0.01 mg / kg or less, or 0.001 mg / kg or less. In certain embodiments, the dosage may vary over the course of treatment. For example, in certain embodiments, the first dosage may be higher than the subsequent dosage. In certain embodiments, the dosage may vary over the course of treatment depending on the subject's response.

[0068]

[0087] Dosage regimen can be adjusted to achieve optimal desired response (e.g., therapeutic response).In certain embodiments, the pharmaceutical composition provided herein is administered to the subject once or over a series of treatments.In certain embodiments, the pharmaceutical composition provided herein is administered to the subject by one or multiple separate administrations or by continuous infusion, depending on the type and severity of disease.

[0069]

[0088] The pharmaceutical compositions provided herein may be administered by any route known in the art, such as, for example, parenteral (e.g., subcutaneous, intraperitoneal, intravenous, including intravenous infusion, intramuscular, intradermal, or intrathecal injection) or enteral (e.g., oral, intranasal, intraocular, sublingual, rectal, or topical) routes.

[0070]

[0089] In some embodiments, the pharmaceutical composition is administered to the central nervous system. In some embodiments, the pharmaceutical composition is administered via spinal injection, intrathecal injection, intraventricular injection, intracerebral injection, or intrahippocampal injection. In some embodiments, the pharmaceutical composition provided herein is administered by intrathecal route. As used herein, the term "intrathecal administration", "intrathecal injection", "intrathecal delivery", or grammatical equivalents refer to injection into the spinal canal (the intrathecal space surrounding the spinal cord). In some embodiments, "intrathecal administration" or "intrathecal delivery" according to the present disclosure refers to IT administration or delivery via the lumbar area or region (i.e., lumbar IT administration or delivery) or cisterna magna delivery (i.e., injection via the opening between the skull and the top of the spine, through the space around and below the cerebellum).

[0071]

[0090] The following examples are provided to better illustrate the claimed invention and are not to be construed as limiting the scope of the invention in any way. All specific compositions, materials, and methods described below are entirely or partially within the scope of the present invention. These specific compositions, materials, and methods are not intended to limit the present invention, but are merely intended to illustrate specific embodiments within the scope of the present invention. Those skilled in the art can develop equivalent compositions, materials, and methods without exercising inventive ability and without departing from the scope of the present invention. It will be understood that many modifications can be made in the procedures described herein, but these modifications are still within the scope of the present invention. It is the intention of the inventors that such modifications are within the scope of the present invention. EXAMPLES

[0072] Example 1

[0091] This example describes the effects of polypeptides RJK001-RJK004 and control polypeptides RJK005-RJK007 on dissolving aggregates of FUS protein, TDP-43 protein, TIA1 protein, and C9orf72 protein.

[0073]

[0092] An in vitro system was prepared in which aggregates of FUS protein (concentration 10 μM), TDP-43 protein (concentration 10 μM), TIA1 protein (concentration 30 μM), and C9orf72 protein (concentration 10 μM, 10% PEG) were formed. Under pH 7.5 conditions, 10 μM of polypeptides RJK001-RJK004 and control polypeptides RJK005-RJK007 were added to the system. Using a confocal laser microscope, the effects of polypeptides RJK001-RJK004 and RJK005-RJK007 on the aggregation of FUS protein, TDP-43 protein, TIA1 protein, and C9orf72 protein were observed, and the results are shown in Figures 2-5.

[0074]

[0093] As shown in Figure 2, 10 μM of polypeptides RJK001-RJK004 and RJK005-RJK007 were added to seven similar FUS protein solutions (pH 7.5, 10 μM FUS), respectively, with aggregates. The effects of RJK001-RJK004 and RJK005-RJK007 on the aggregation of FUS protein were observed. The image on the left is an image immediately after the addition of the polypeptide. The image in the middle is a microscopic image when the polypeptide was added for 40 seconds. The image on the right is a microscopic image when the polypeptide was added for 80 seconds. From Figure 2, it can be clearly observed that the FUS protein solution showed typical aggregation (phase-separated droplets) immediately (0 seconds) after the addition of peptides RJK001-RJK004. 40 seconds after the addition of polypeptides RJK001-RJK004, the aggregation of FUS protein was significantly reduced (phase-separated droplets were significantly reduced). 80 seconds after adding the polypeptides RJK001-RJK004, the FUS protein aggregation almost disappeared (few phase-separated droplets). Therefore, the polypeptides RJK001-RJK004 can significantly dissolve the FUS protein aggregation. However, after adding the polypeptides RJK005-RJK007, the FUS protein solution still showed typical aggregation (phase-separated droplets). Therefore, the polypeptides RJK005-RJK007 cannot effectively dissolve the FUS aggregates.

[0075]

[0094] As shown in Figure 3, 10 μM of polypeptides RJK001-RJK004 and RJK005-RJK007 were added to seven similar TDP-43 protein solutions (pH 7.5, 10 μM of TDP-43), respectively, with aggregates. The effects of RJK001-RJK004 and RJK005-RJK007 on the aggregation of TDP-43 protein were observed. The image on the left is an image immediately after the addition of the polypeptide. The image in the middle is a microscopic image when the polypeptide was added for 40 seconds. The image on the right is a microscopic image when the polypeptide was added for 80 seconds. From Figure 3, it can be clearly observed that the TDP-43 protein solution showed typical aggregation (phase-separated droplets) immediately (0 seconds) after the addition of peptides RJK001-RJK004. 40 seconds after the addition of the polypeptides RJK001-RJK004, the aggregation of the TDP43 protein was significantly reduced (phase-separated droplets were significantly reduced). 80 seconds after the addition of the polypeptides RJK001-RJK004, the aggregation of the TDP43 protein almost disappeared (few phase-separated droplets). Therefore, the polypeptides RJK001-RJK004 can significantly dissolve the aggregation of the TDP43 protein. However, after the addition of the polypeptides RJK005-RJK007, the TDP43 protein solution still showed typical aggregation (phase-separated droplets). Therefore, the polypeptides RJK005-RJK007 cannot effectively dissolve the TDP43 aggregates.

[0076]

[0095] As shown in Figure 4, 90 μM of polypeptides RJK001-RJK004 and RJK005-RJK007 were added to seven similar TIA1 protein solutions (pH 7.5, 30 μM of TIA1) with aggregates, respectively. The effects of RJK001-RJK004 and RJK005-RJK007 on the aggregates of TIA1 protein were observed. The image on the left is an image immediately after the addition of the polypeptide. The image in the middle is a microscopic image when the polypeptide was added for 40 seconds. The image on the right is a microscopic image when the polypeptide was added for 80 seconds. From Figure 4, it can be clearly observed that the TIA1 protein solution showed typical aggregation (phase-separated droplets) immediately (0 seconds) after the addition of peptides RJK001-RJK004. 40 seconds after the addition of the polypeptides RJK001-RJK004, the aggregation of TIA1 protein was significantly reduced (phase-separated droplets were significantly reduced). 80 seconds after the addition of the polypeptides RJK001-RJK004, the aggregation of TIA1 protein almost disappeared (few phase-separated droplets). Therefore, the polypeptides RJK001-RJK004 can significantly dissolve the aggregation of TIA1 protein. However, after the addition of the polypeptides RJK005-RJK007, the TIA1 protein solution still showed typical aggregation (phase-separated droplets). Therefore, the polypeptides RJK005-RJK007 cannot effectively dissolve the TIA1 aggregates.

[0077]

[0096] As shown in Figure 5, 90 μM of polypeptides RJK001-RJK004 and RJK005-RJK007 were added to seven similar GR50-GFP (translated from the non-coding gene C9orf72) protein solutions (pH 7.5, 10 μM) with aggregates, respectively. The effect of RJK001-RJK004 and RJK005-RJK007 on the aggregation of GR50-GFP protein was observed. The image on the left is an image immediately after the addition of the polypeptide. The image in the middle is a microscopic image when the polypeptide was added for 40 seconds. The image on the right is a microscopic image when the polypeptide was added for 80 seconds. From Figure 5, it can be clearly observed that the GR50-GFP protein solution showed typical aggregation (phase-separated droplets) immediately (0 seconds) after the addition of peptides RJK001-RJK004. 40 seconds after the addition of polypeptides RJK001-RJK004, the aggregation of GR50-GFP protein was significantly reduced (phase-separated droplets were significantly reduced). 80 seconds after the addition of polypeptides RJK001-RJK004, the aggregation of GR50-GFP protein almost disappeared (few phase-separated droplets). Therefore, polypeptides RJK001-RJK004 can significantly dissolve the aggregation of TIA1 protein. However, after the addition of polypeptides RJK005-RJK007, the GR50-GFP protein solution still showed typical aggregation (phase-separated droplets). Therefore, polypeptides RJK005-RJK007 cannot effectively dissolve GR50-GFP aggregates.

[0078]

[0097] Therefore, in accordance with the above observations, the polypeptides RJK001 to RJK004 had obvious lytic effects on the in vitro aggregation of FUS protein, TDP-43 protein, TIA1 protein, and C9orf72 protein, while the polypeptides RJK005 to RJK007 in which the E residue was mutated to Q had no lytic effect.

[0079] Example 2

[0098] This example describes the preparation of the SH-SY5Y cell model.

[0099] SH-SY5Y cell models overexpressing FUS-GFP or TDP-43-mCherry proteins were generated using the following steps.

[0080]

[0100] Cultivation of SH-SY5Y cells

[0101] SH-SY5Y cells were cultured in DMEM / F12 medium containing 10% fetal bovine serum at 37°C in a 5% carbon dioxide incubator. After the cells reached 80% confluence, the culture medium was removed using a vacuum pump or pipette. The cells were washed once with PBS. Trypsin-EDTA (0.05%) was added to the culture dish, which was incubated for 1 min in a 37°C cell incubator. A predetermined amount of culture medium was added twice to stop the digestion, and the cells were gently blown on to suspend the cells into a uniform cell suspension. The cell suspension was added to a 15 mL centrifuge tube and centrifuged at 1200 rpm for 3 min. The supernatant was discarded, and the cells were resuspended in fresh complete medium. The cells were added back to the culture dish, and the cells were passaged 1:6 to 1:4.

[0081]

[0102] Transfection of SH-SY5Y cells

[0103] To generate the SH-SY5Y cell model transfected with FUS plasmid, 3ug of pCMV7.1-FUS-GFP plasmid and 6ug of liposome were dissolved in 100ul of NaCl, respectively. The liposome solution was added to the DNA, mixed well, and left at room temperature for 15-30 minutes. The above liquid was added to the cultured cells and mixed well. The cell culture was observed after 24 hours.

[0104] The transfection procedure of pCMV7.1-TDP43-mCherry plasmid is the same as above.

[0082] Example 3

[0105] This example illustrates the lytic effect of RJK001 polypeptide on the aggregation of FUS protein, TIA1 protein, and TDP-43 protein in cells.

[0083]

[0106] The SH-SY5Y cell model transfected with FUS plasmid according to Example 2 (initially cultured at 37°C) was placed in a 42°C incubator for 1 hour for heat shock treatment to cause aggregation of FUS protein. 1 μg of RJK001 polypeptide-plasmid was added to the cells of the RJK001 experimental group. RJK005~RJK007 polypeptide-plasmid was added to the cells of the control group. After 1 hour, the cells were removed, the membrane was fixed, and the SH-SY5Y-labeled stress granule protein G3BP1 was immunofluorescently stained according to conventional immunofluorescence staining procedures. A laser confocal fluorescence microscope was used to observe the accumulation of overexpressed FUS in SH-SY5Y cells. As shown in Figure 6, after 1 hour of heat shock treatment at 42°C, the number of phase-separated droplets of FUS protein and TIA1 protein in the RJK001 group was significantly less than that in the RJK005~RJK007 control group.

[0084]

[0107] The SH-SY5Y cell model (initially cultured at 37°C) transfected with the TDP-43 plasmid prepared according to Example 2 was placed in a 42°C incubator for 1 hour for heat shock treatment to separate and aggregate the TDP43 protein. 1 μg of RJK001 polypeptide-plasmid was added to the cells of the RJK001 experimental group. RJK005~RJK007 polypeptide-plasmid was added to the cells of the control group. After 1 hour, the cells were removed, the membrane was fixed, and the proteins labeled in SH-SY5Y were immunofluorescently stained according to conventional immunofluorescence staining procedures. Laser confocal fluorescence microscopy was used to observe the accumulation of TDP-43 and cell-intrinsic G3BP1 in SH-SY5Y cells. As shown in Figure 7, after 1 hour of heat shock treatment at 42°C, the number of phase-separated droplets of TDP-43 protein in the experimental group was significantly less than that in the control group.

[0085]

[0108] Therefore, in accordance with the above observations, the RJK001 polypeptide has a significant lytic effect on the aggregation of FUS protein, TIA1 protein, and TDP-43 protein in the SH-SY5Y cell model.

[0086] Example 4

[0109] This example describes the preparation of an ALS rat motor neuron model.

[0110] An ALS rat motor neuron model that can be used to overexpress FUS-GFP and SOD1(G93A) proteins was generated using the following steps.

[0087]

[0111] Isolation and culture of rat motoneurons

[0112] After anesthetizing E13.5 rats, open the abdominal cavity and remove the uterus to a 10 cm dish. Add HBSS and remove the embryo to a new 10 cm dish using scissors and tweezers. Separate the head and body of the embryo and move it to the anatomical spinal cord under a stereoscope. Turn the body upwards and fix the hind limbs with ultra-small forceps. Once the translucent spine is found, use another ultra-small forceps to pull the skin forward and upwards, then open the joints beside the spine. Pull the spine up from the tail. Fix the head of the spine with the dorsal side facing up and pull the membrane up. Turn the rat over so that the abdomen is facing up, peel off the membrane, and remove most of the DRG. Remove the DRG attached to the spinal cord and transfer to a new 6 cm dish. Transfer the spinal cord to a 5ml centrifuge tube using microtweezers, crush the spinal cord to a size of 1mm using tweezers, add 1x trypsin (diluted in HBSS), and place in a 37°C incubator for 25-30 minutes. Using a 1ml pipette tip, suck the tissue clump into 3ml pre-warmed MN medium, and blow the tissue clump apart. Pass through a 40um filter, transfer the cells to a 5ml centrifuge tube, centrifuge at 400g for 5 minutes, and remove the supernatant. Resuspend the cells in 3ml MN medium, remove 10ul, and count. 1.05x10 6Cells are seeded in a small confocal dish, 700ul of MN medium, allowed to adhere to the wall for 30 minutes to an hour, and 800ul of medium is added. Before seeding the cells, the cells are transferred to two centrifuge tubes for centrifugation. One cell centrifuge tube is resuspended in 800ul of electroporation solution, split into four plasmid groups, and then electrotransfected with Lonza 2b. After electrotransfection, transfer to 1ml of MN medium as soon as possible to make those that were not electrotransfected. The cells are then transferred to a small confocal dish, left in the incubator for 2 hours to allow them to adhere to the wall, and then the MN medium is replaced to remove as much of the electroporation solution as possible.

[0088]

[0113] Transfection of rat motor neurons

[0114] Transfer calcium to DIV7 and calculate the bottom area of ​​the dish as well as the amount of CaCl2 and HBS. Replace the liquid in the medium with pre-warmed Neurobasal and collect the old medium for use. Add 500ng of plasmid to 12.5ul of 0.3M CaCl2 and quickly pipette up and down 20-30 times to mix well. Add 12.5ul of HBS (pH 6.95-7.0) to the centrifuge tube and store this in -20 aliquots. Quickly aspirate and mix, paying attention to the pH. Add liquid to each well and rotate your wrist to mix the culture medium into the neurons and place this back in the incubator for 60 minutes, small particles can be seen at the bottom of the dish. Pre-bubble the Neurobasal medium by passing CO2 through for 15 minutes until it turns yellow and does not change color any more. Filter through a 0.22um filter for later use. Remove the culture medium on the neurons, add Neurobasal saturated with CO2, and place it back in the incubator for 15 minutes to observe the small particles in the dish disappear. Filter the old medium, add new medium 1:1, and replace the Neurobasal in the dish 1:1 with medium. Return to the incubator.

[0089] Example 5

[0115] This example illustrates the lytic effect of the RJK001 polypeptide on aggregates of FUS protein, a pathogenic protein of ALS, in rat motor neurons.

[0090]

[0116] A rat motor neuron model of pathogenic FUS protein aggregates in ALS was prepared according to Example 4. RJK001 polypeptide (20 μM) was added to the model in the experimental group, and RJK005 polypeptide was added to the control group. The lytic effect of the polypeptide on protein aggregates in motor neurons was recorded by live imaging using a laser confocal fluorescence microscope. Figure 8 shows microscopic images of single cells, in which the upper panel is the experimental group (RJK001) and the lower panel is the control group (RJK005). In each image panel, the leftmost image is an image of motor neurons and protein aggregates on the 10th day of in vitro culture. The two to three images from the left are microscopic images immediately after the addition of the polypeptide (0 min). The middle images are microscopic images at different time points (30 min, 60 min, 90 min) after the addition of the polypeptide, and the rightmost image is a microscopic image 120 min after the addition of the polypeptide.

[0091]

[0117] As shown in Figure 8, the ALS pathogenic protein aggregates in the experimental group began to dissolve significantly 90 minutes after the addition of the polypeptide RJK001, and were essentially dissolved after 120 minutes, while dissolution of the aggregates did not occur in the control group. Therefore, the RJK001 polypeptide has a significant dissolving effect on FUS protein aggregates in the rat motor neuron model.

[0092] Example 6

[0118] This example illustrates the lytic effect of the RJK001 polypeptide on aggregates of SOD1(G93A) protein, a pathogenic protein of ALS, in rat motor neurons.

[0093]

[0119] A rat motor neuron model of pathogenic SOD1 (G93A) protein aggregates of ALS was prepared according to Example 4. RJK001 polypeptide (20 μM) was added to the model of the experimental group, and RJK005 polypeptide was added to the control group. The dissolving effect of the polypeptide on protein aggregates in motor neurons was recorded by live image using a laser confocal fluorescence microscope. Figure 9 shows the microscopic images of single cells, in which the left panel is the experimental group (RJK001) and the right panel is the control group (RJK005). In each image panel, the left image is the image immediately after adding the polypeptide (0 min). The right image is the microscopic image 24 hours after adding the polypeptide.

[0094]

[0120] As shown in Figure 9, the aggregates of ALS pathogenic protein in the experimental group were significantly dissolved 24 hours after adding the polypeptide RJK001, while the aggregates were not dissolved in the control group. Therefore, the RJK001 polypeptide has a significant dissolving effect on the aggregates of ALS pathogenic SOD1(G93A) protein in the rat motor neuron model.

[0095] Example 7

[0121] This example illustrates that intrathecal injection of a virus having the AAV2-9 serotype containing the RJK001 polypeptide dissolved in vivo aggregates of SOD1(G93A) protein, a pathogenic protein in ALS.

[0096]

[0122] hSOD1(G93A) transgenic mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA) and genotypes were confirmed. Mice were randomly divided into three groups at 8 weeks of age: the first group was intrathecally injected with 10ul normal saline after anesthesia, the second group (RJK001 experimental group) was intrathecally injected with AAV2-9 serotype RJK001, and the third group (RJK005 control group) was intrathecally injected with AAV2-9 serotype RJK005.

[0097]

[0123] Six weeks after injection, open field experiments were performed on the mice, and the walking score was recorded as the time taken per unit distance. The longer the time, the worse the motor ability. As shown in Figure 10, compared with the normal saline and RJK005 control groups, the motor ability of the mice in the experimental group was significantly improved.

[0098] Example 8

[0124] This example illustrates the effect of polypeptides RJG001-RJG003 on dissolving aggregates of FUS protein.

[0099]

[0125] An in vitro system was prepared in which aggregates of FUS protein (concentration 10 μM) were formed. Under pH 7.5 conditions, 30 μM of polypeptides RJG001 to RJG003 and control polypeptide RJK005 were each added to the system. Using a confocal laser microscope, the effects of polypeptides RJG001 to RJG003 and RJK005 on FUS protein aggregation were observed, and the results are shown in FIG. 11.

[0100]

[0126] As shown in FIG. 11, the FUS protein solution showed typical aggregation (phase-separated droplets) immediately (0 seconds) after the addition of the polypeptides RJG001-RJG003. 40 seconds after the addition of the polypeptides, the aggregation of the FUS protein was reduced (phase-separated droplets were reduced). 80 seconds after the addition of the polypeptides RJG001-RJG003, the aggregation of the FUS protein was significantly reduced. Therefore, the polypeptides RJG001-RJG003 can significantly dissolve the aggregation of the FUS protein. However, after the addition of the polypeptide RJK005, the FUS protein solution still showed typical aggregation (phase-separated droplets). Therefore, the polypeptides RJG001-RJG003 cannot effectively dissolve the FUS aggregates.

[0101] Example 9

[0127] This example illustrates the lytic effect of RJG001-RJG003 polypeptides on the aggregation of FUS protein in cells.

[0102]

[0128] The SH-SY5Y cell model transfected with FUS plasmid according to Example 2 (initially cultured at 37°C) was placed in a 42°C incubator for 1 hour for heat shock treatment to cause FUS protein aggregation. 1 μg of RJG001, RJG002, or RJG003 polypeptide-plasmid was added to the cells in the experimental group. RJK005 polypeptide was added to the cells in the control group. After 1 hour, the cells were removed, the membrane was fixed, and the stress granule protein G3BP1 labeled in SH-SY5Y was immunofluorescently stained according to conventional immunofluorescence staining procedures. The accumulation of overexpressed FUS in SH-SY5Y cells was observed using a laser confocal fluorescence microscope.

[0103]

[0129] As shown in Figure 12, after 1 h of heat shock treatment at 42 °C, the number of phase-separated droplets of FUS protein in the experimental groups was significantly lower than that in the RJK005 control group. Therefore, RJG001-RJG003 could significantly dissolve the aggregation of FUS protein in the SH-SY5Y cell model.

[0104]

[0130] While the present invention has been particularly shown and described with reference to specific embodiments, some of which are preferred embodiments, it will be understood by those skilled in the art that various changes in form and details can be made in the specific embodiments without departing from the spirit and scope of the invention disclosed herein. In one aspect, the present invention may be as follows. [Aspect 1] A polypeptide comprising a hydrophilic segment and a hydrophobic segment, the hydrophilic segment having a length of 10 to 20 amino acid residues, at least 50% of which are Asp, Glu, Lys, or Arg; the hydrophobic segment has a length of 10 to 20 amino acid residues, at least 50% of which are Tyr, Phe, Trp, Leu, Ile, Val, Met, Pro, Ala, or Cys; the hydrophilic segment is at the N-terminus and the hydrophobic segment is at the C-terminus, or vice versa; The polypeptide has a length of 20 to 60 amino acid residues, The above polypeptide, wherein the polypeptide is capable of dissolving protein aggregates. [Aspect 2] The hydrophilic segment is TX1PQX1X1SX1X1X1VX1X1PX1X1X1 (SEQ ID NO: 11), X1LX1X1X1SX1X1X1VX1X1X1QX1X1X1 (SEQ ID NO: 12), X1X1X1VX1X1X1X1X1VX1X1 (SEQ ID NO: 13), and X1X1SX1VQX1LX1 (SEQ ID NO: 14) having a sequence selected from 2. The polypeptide of embodiment 1, wherein X1 is Asp, Glu, Lys, or Arg. [Aspect 3] The hydrophilic segment is TEPQEESEEEVEEPEER (SEQ ID NO: 15), TDPQDDSDDDVDDPDDR (SEQ ID NO: 16), TKPQKKSKKKVKKPKKR (SEQ ID NO: 17), TRPQRRSRRRVRRPRRR (SEQ ID NO: 18), ELDEESEDEVEEEQEDR (SEQ ID NO: 19), KEEVDEDRDVDE (SEQ ID NO: 20), and EKSEQDLE (SEQ ID NO:21) A sequence selected from or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto. 2. The polypeptide of embodiment 1, having the following structure: [Aspect 4] The hydrophobic segment is TFYDQTVSNDL (SEQ ID NO: 22), ANSAYYDAHPVTNGI (SEQ ID NO:23), PPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 24), and EGEVAEEPNSRP (SEQ ID NO: 25) A sequence selected from or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto. 2. The polypeptide of embodiment 1, having the following structure: [Aspect 5] TEPQEESEEEVEEPEERQQTPEVVPDDSGTFYDQTVSNDLE (SEQ ID NO: 1), TDPQDDSDDDVDDPDDRQQTPDVVPDDSGTFYDQTVSNDLD (SEQ ID NO: 2), TKPQKKSKKKVKKPKKRQQTPKVVPDDSGTFYDQTVSNDLK (SEQ ID NO: 3), TRPQRRSRRRVRRPRRRQQTPRVVPDDSGTFYDQTVSNDLR (SEQ ID NO: 4), ELDEESEDEVEEEQEDRQPSPEPVQENANSAYYDAHPVTNGIE (SEQ ID NO: 8), KEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 9), and EGEVAEEPNSRPQEKSEQDLE (SEQ ID NO: 10) A sequence selected from or a sequence having at least 90% identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue differences thereto. 2. The polypeptide of embodiment 1, having the following structure: [Aspect 6] The polypeptide according to aspect 1, wherein the protein aggregate is a FUS aggregate, a TDP43 aggregate, a TIA1 aggregate, a C9orf72 aggregate, or a combination thereof. [Aspect 7] A polynucleotide encoding the polypeptide according to any one of aspects 1 to 6. [Aspect 8] A polynucleotide according to Aspect 7, which is DNA or RNA. [Aspect 9] A vector comprising the polynucleotide described in aspect 7 or 8. [Aspect 10] The vector according to aspect 9, which is a viral vector. [Aspect 11] The vector described in Aspect 10, which is an AAV vector. [Aspect 12] A recombinant virus comprising the polynucleotide described in aspect 7 or 8. [Aspect 13] The recombinant virus described in Aspect 12, which is AAV. [Aspect 14] A host cell comprising the polynucleotide described in aspect 7 or 8. [Aspect 15] (1) a pharmaceutical composition comprising the polypeptide according to any one of Aspects 1 to 6, the polynucleotide according to Aspect 7 or 8, the vector according to Aspect 9 to 11, the recombinant virus according to Aspect 12 or 13, or the host cell according to Aspect 14, and (2) a pharma- ceutically acceptable carrier. [Aspect 16] A method for dissolving protein aggregates in a cell, the method comprising the step of introducing the polypeptide according to any one of aspects 1 to 6 into a cell. [Aspect 17] The method of aspect 16, wherein the cell is a neuronal cell. [Aspect 18] The method of aspect 16, wherein the protein aggregate is a FUS aggregate and the cell is a motor neuron. [Aspect 19] The method of aspect 16, wherein the cell is in vitro or in vivo. [Aspect 20] A method for treating a neurodegenerative disease in a subject in need of such treatment, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described in Aspect 15. [Aspect 21] The method of aspect 20, wherein the neurodegenerative disease is selected from frontotemporal dementia, amyotrophic lateral sclerosis, corticobasal degeneration, dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic grain disease, Alzheimer's disease, Kii Peninsula Parkinson's / dementia complex, progressive supranuclear palsy, and Pick's disease. [Aspect 22] The method of aspect 20, wherein the pharmaceutical composition is administered to the central nervous system. [Aspect 23] The method of aspect 22, wherein the pharmaceutical composition is administered via spinal injection, intrathecal injection, intraventricular injection, intracerebral injection, or intrahippocampal injection. [Aspect 24] A method for identifying a polypeptide capable of dissolving protein aggregates, comprising: Identifying a protein having a modified region, the modified region comprising: (a) at least two amino acid residues consisting of Gln; (b) at least six hydrophilic amino acid residues selected from Arg, Lys, Asp, Glu, and Asn; and (c) at least six hydrophobic amino acid residues selected from Phe, Cys, Leu, Val, and Ile; including, steps; Producing a polypeptide consisting of a denatured region; contacting the polypeptide with the protein aggregate; and Determining that the polypeptide dissolves protein aggregates. The above method. [Aspect 25] The method described in aspect 24, wherein the polypeptide has a length of 20 to 60 amino acid residues. [Aspect 26] The method according to aspect 24, wherein the polypeptide comprises a hydrophilic segment at the N-terminus and a hydrophobic segment at the C-terminus, or vice versa. [Aspect 27] The method according to aspect 24, wherein the protein is a natural, intrinsically disordered protein. [Aspect 28] The method described in aspect 24, wherein the protein aggregate is a FUS aggregate, a TDP43 aggregate, a TIA1 aggregate, or a C9orf72 aggregate.

Claims

1. 1. A polypeptide comprising a hydrophilic segment and a hydrophobic segment, the polypeptide is capable of dissolving protein aggregates; and TEPQEESEEEVEEPEEERQQTPEVVPDDSGTFYDQTVSNDLE (SEQ ID NO: 1), TDPQDDSDDDDVDDDPDDDRQQTPDVVPDDSGTFYDQTVSNDLD (SEQ ID NO: 2), TKPQKKSKKKVKKPKKRQQTPKVVPDDSGTFYDQTVSNDLK (SEQ ID NO: 3), TRPQRRSRRRVRRPRRRQQTPRVVPDDSGTFYDQTVSNDLR (SEQ ID NO: 4), ELDEESEDEVEEEQEDRQPSPEPVQENANSAYYDAHPVTNGIE (SEQ ID NO: 8), KEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAAREATSIPGFPAEGAIPLPV (SEQ ID NO: 9), and EGEVAEEEPNSRPQEKSEQDLE (SEQ ID NO: 10) comprising a sequence selected from The above polypeptide.

2. 2. The polypeptide of claim 1, wherein the protein aggregate is a FUS aggregate, a TDP43 aggregate, a TIA1 aggregate, a C9orf72 aggregate, or a combination thereof.

3. A polynucleotide encoding the polypeptide of claim 1 or 2.

4. The polynucleotide of claim 3 which is DNA or RNA.

5. A vector comprising the polynucleotide of claim 3 or 4.

6. The vector of claim 5 which is a viral vector.

7. The vector of claim 6 which is an AAV vector.

8. A recombinant virus comprising the polynucleotide of claim 3 or 4.

9. The recombinant virus of claim 8 which is an AAV.

10. A host cell comprising the polynucleotide of claim 3 or 4.

11. A pharmaceutical composition comprising (1) a polypeptide according to claim 1 or 2, a polynucleotide according to claim 3 or 4, a vector according to any one of claims 5 to 7, a recombinant virus according to claim 8 or 9, or a host cell according to claim 10, and (2) a pharma- ceutical acceptable carrier.

12. 13. A method for dissolving protein aggregates in a cell, comprising the step of introducing a polypeptide according to claim 1 or 2 into a cell (excluding introduction into a human).

13. The method of claim 12, wherein the cell is a neuronal cell.

14. 14. The method of claim 12 or 13, wherein the protein aggregates are FUS aggregates and the cells are motor neurons.

15. The method of any one of claims 12 to 14, wherein the cell is in vitro or in vivo.

16. The pharmaceutical composition according to claim 11 for treating a neurodegenerative disease.

17. 17. The pharmaceutical composition of claim 16, wherein the neurodegenerative disease is selected from frontotemporal dementia, amyotrophic lateral sclerosis, corticobasal degeneration, dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, argyrophilic grain disease, Alzheimer's disease, Kii Peninsula Parkinson's / dementia complex, progressive supranuclear palsy, and Pick's disease.

18. 18. The pharmaceutical composition of claim 16 or 17, which is administered to the central nervous system.

19. 20. The pharmaceutical composition of claim 18, administered via spinal, intrathecal, intraventricular, intracerebral, or intrahippocampal injection.

Citation Information

Patent Citations

  • Histone deacetylase (hdac) biomarkers in multiple myeloma

    JP2016523236A